Twist Bioscience Corporation TWST NGS applications — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Twist Bioscience Corporation's ngs applications — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Twist Bioscience Corporation's NGS applications — revenue?
- Twist Bioscience Corporation (TWST) reported NGS applications — revenue of $57.44M in Q1 2026.
- How has Twist Bioscience Corporation's NGS applications — revenue changed year-over-year?
- Twist Bioscience Corporation's NGS applications — revenue increased by 12.3% year-over-year, from $51.15M to $57.44M.
- What is the long-term trend for Twist Bioscience Corporation's NGS applications — revenue?
- Over 4 years (2021 to 2025), Twist Bioscience Corporation's NGS applications — revenue has grown at a 30.1% compound annual growth rate (CAGR), from $72.67M to $208.1M.
- What does NGS applications — revenue mean?
- This metric represents the total revenue generated from the sale of products and services specifically designed for Next-Generation Sequencing (NGS) workflows. It captures the financial performance of tools used in library preparation and target enrichment, reflecting the company's market penetration in genomics and precision medicine. Growth in this segment indicates successful adoption of the company's synthetic DNA platform within the broader sequencing ecosystem.